Price Alert: Shares of VolitionRX (VNRX) Trade 19.19% Higher at Midday May 13

Equities Staff  |

Today VolitionRX Ltd (NYSE: VNRX) is trading 19.19% up.

The latest price, as of 12:08:24 est, was $2.52. VolitionRX has moved $0.405 over the previous day’s close.

101,850 shares have traded hands.

As of the previous close, VolitionRX has moved YTD 32.80%. The company expects its next earnings on 2022-08-11.

For technical charts, analysis, and more on VolitionRX visit the company profile.

About VolitionRX Ltd

Volition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

To get more information on VolitionRX Ltd and to follow the company's latest updates, you can visit the company's profile page here: VolitionRX Ltd's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan
Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast
Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement
Target Hits 52-Week Low After Missing Badly on First Quarter Earnings
DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter
Another Crypto Winter Wipes Out Billions in Market Value
Inflation + Recession = Recipe for Volatility



Market Movers

Sponsored Financial Content